Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Fujioka

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 8, 2007
[Methods for quantitative analysis of serum remnant-like particle cholesterol]Yoshio Fujioka
Circulation Journal : Official Journal of the Japanese Circulation Society|September 14, 2012
How do we treat body fat percentages determined by bioelectrical impedance analysis?Yoshio Fujioka
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 12, 2013
[Clinical science relating atherosclerotic diseases and hypertriglyceridemia]Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|October 20, 2017
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemiaYoshio Fujioka
Journal of Atherosclerosis and Thrombosis|September 10, 2025
Does Pemafibrate Lower Low-Density Lipoprotein-Cholesterol?Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|November 13, 2024
The Clinical Implication of Pemafibrate, a Novel Selective PPARα ModulatorYoshio Fujioka
Journal of Atherosclerosis and Thrombosis|September 14, 2018
Problems that Physicians should Notice for Better Treatment of Hypercholesterolemia in JapanYoshio Fujioka
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 13, 2012
[What is a good marker for serum cholesterol to identify high-risk patients at general health checks?]Yoshio Fujioka
Clinical Calcium|March 1, 2016
[Nutrition and atherosclerotic cardiovascular disease]Wao Tsutsui, Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|June 27, 2009
Remnant lipoproteins as strong key particles to atherogenesisYoshio Fujioka, Yuichi Ishikawa
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 8, 2007
[Methods for quantitative analysis of serum remnant-like particle cholesterol]Yoshio Fujioka
Circulation Journal : Official Journal of the Japanese Circulation Society|September 14, 2012
How do we treat body fat percentages determined by bioelectrical impedance analysis?Yoshio Fujioka
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 12, 2013
[Clinical science relating atherosclerotic diseases and hypertriglyceridemia]Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|October 20, 2017
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemiaYoshio Fujioka
Journal of Atherosclerosis and Thrombosis|September 10, 2025
Does Pemafibrate Lower Low-Density Lipoprotein-Cholesterol?Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|November 13, 2024
The Clinical Implication of Pemafibrate, a Novel Selective PPARα ModulatorYoshio Fujioka
Journal of Atherosclerosis and Thrombosis|September 14, 2018
Problems that Physicians should Notice for Better Treatment of Hypercholesterolemia in JapanYoshio Fujioka
Rinsho Byori. the Japanese Journal of Clinical Pathology|June 13, 2012
[What is a good marker for serum cholesterol to identify high-risk patients at general health checks?]Yoshio Fujioka
Clinical Calcium|March 1, 2016
[Nutrition and atherosclerotic cardiovascular disease]Wao Tsutsui, Yoshio Fujioka
Journal of Atherosclerosis and Thrombosis|June 27, 2009
Remnant lipoproteins as strong key particles to atherogenesisYoshio Fujioka, Yuichi Ishikawa
Pageof 7